AstraZeneca (NYSE:AZN) announces the results from an international real-world study, called CVD-REAL, of patients with type 2 diabetes (T2D) who were treated with SGLT-2 inhibitors. The data were presented at the American College of Cardiology 66th Annual Scientific Session.
CVD-REAL assessed data from more than 300K T2D patients across six countries, 87% had no history of cardiovascular disease. The data showed that treatment with SGLT-2 inhibitors [AstraZeneca's Farxiga (dapagliflozin); Janssen's Invokana (canagliflozin); Eli Lilly and Boehringer Ingelheim's Jardiance (empagliflozin)] reduced the risk of hospitalization for heart failure by 39% (hazard ratio = 0.61; p<0.001) and death from any cause by 51% (hazard ratio = 0.49; p<0.001).
For the composite endpoint of hospitalization for heart failure and all-cause mortality, the reduction in risk was 46% (hazard ratio = 0.54; p<0.001).
The study data were obtained from medical records, claims databases and national registers and were not independently adjudicated/verified against source documents.
Bruce Cooper, MD, Vice President and Head of Global Medical Affairs at AstraZeneca, says, “Diabetes is a growing epidemic worldwide, which is associated with significant comorbidities that contribute to an increased risk of costly hospitalizations and even death. Real-world data from this study provide striking evidence that the newer SGLT-2i class of medicines cuts the rate of hospitalizations for heart failure and death by approximately half. CVD-REAL is the first study to observe these effects of SGLT-2i treatment in a much broader and lower risk group of type-2 diabetes patients than previously evaluated in clinical trials.”
Now read: I Would Not Chase AstraZeneca In 2017 »